• Mutation; HGNC; 583; APC; Simple; p.Thr1556Leufs*9 (c.4666delA); ClinVar=VCV000156477; Zygosity=Heterozygous (from parent cell line).
  
• Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Leu (c.1514G>T); ClinVar=VCV000376424; Zygosity=Heterozygous (from parent cell line).
  
• Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line).
  
• Mutation; HGNC; 11998; TP53; Simple; p.Ser90Profs*33 (c.267delC); ClinVar=VCV000156515; Zygosity=Homozygous (from parent cell line).
  

PubMed=8094034
Yu D.-H., Wolf J.K., Scanlon M., Price J.E., Hung M.-C.
Enhanced c-erbB-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A.
Cancer Res. 53:891-898(1993)

PubMed=23552738; DOI=10.1038/oncsis.2012.22
Lee J., Bartholomeusz C., Krishnamurthy S., Liu P., Saso H., LaFortune T.A., Hortobagyi G.N., Ueno N.T.
PEA-15 unphosphorylated at both serine 104 and serine 116 inhibits ovarian cancer cell tumorigenicity and progression through blocking beta-catenin.
Oncogenesis 1:e22.1-e22.11(2012)

PubMed=27561551; DOI=10.1038/ncomms12645
Coscia F., Watters K.M., Curtis M., Eckert M.A., Chiang C.-Y., Tyanova S., Montag A., Lastra R.R., Lengyel E., Mann M.
Integrative proteomic profiling of ovarian cancer cell lines reveals precursor cell associated proteins and functional status.
Nat. Commun. 7:12645.1-12645.14(2016)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005
Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P., Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B., Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017)